New York Post - September 05, 2026

Nearly 10K lives lost to 9/11-related illness — including 5,892 from cancer — in 25 years since attacks

Michael Crane, MD, MPH, discusses research finding that a staggering 5,892 first responders and people who lived and worked near Ground Zero have died from cancer linked to toxic air in the 25 years since September 11, 2001—more than double the 2,753 people killed in the terror attacks.

35.2M Reach

New York Post - September 08, 2026

Mount Sinai doctors knew 9/11's health toll would last decades. They're still seeing it 25 years later

Michael Crane, MD, MPH, Craig Katz, MD, and Raja Flores, MD, discuss how the research on the aftermath of 9/11 has evolved over the past 25 years, as well as Mount Sinai's effort to understand and treat the lasting health effects of the attack.

32.9M Reach

CBS News - September 07, 2026

September 11 first responders are still suffering health impacts after 25 years

Michael Crane, MD, MPH, discusses the health impacts 9/11 first responders are still suffering from 25 years later.

36M Reach

Sickle Cell Disease News - September 08, 2026

Mount Sinai team to study sickle cell triggers in everyday life

The Icahn School of Medicine at Mount Sinai has received a $4.1 million grant from the National Heart, Lung, and Blood Institute, part of the National Institutes of Health, to study how everyday exposures affect the health of people with sickle cell disease.

8.97k Reach

Urology Times - September 09, 2026

John Sfakianos, MD, discusses evolving management of recurrent LG-IR-NMIBC

John Sfakianos, MD, discusses the challenges of managing recurrent LG-IR-NMIBC and the role of chemoablation.

94.1k Reach

Smithsonian Magazine - September 09, 2026

Peptides Are All the Rage, Promising Miracle Cures and Makeovers Delivered by Injection. How Did We Get Here?

Deborah Doroshow, MD, PhD, discusses the latest peptide craze and how it is part of a broader phenomenon, as patients look beyond the regulated health system to address problems that doctors have struggled to treat.

4.52M Reach

The Cancer Letter - September 16, 2026

25 years after 9/11, a smoking cessation program may have curbed lung cancer risk for first responders at Ground Zero

Michael Crane, MD, MPH, discusses his experience treating patients with 9/11-related illnesses, and how cancer's toll on survivors is still accelerating 25 years later.

No reach data

Associated Press - September 16, 2026

Mount Sinai Surgery Chair Says the MARS2 Trial Is Being Misread by Mesothelioma Patients, Mesothelioma Hope Reports

Raja Flores, MD, discusses a principle from the surgery side of mesothelioma care: who a patient is matters as much as which treatment they get.

28.8M Reach

The New York Times - September 17, 2026

I Lost 3 Brothers to Pancreatic Cancer. I'm Determined Not to Be Next.

New York Times Magazine contributor chronicles his family's history with pancreatic cancer and his experience receiving care at Mount Sinai. Aimee Lucas, MD, Michael Murray, MD, and former genetic counselor Danielle Hoffman are featured.

156M Reach

WWD - Women's Wear Daily - September 18, 2026

Mount Sinai Experts Debunk Myths and Highlight Modifiable Risks for Skin and Breast Cancer

Angela Lamb, MD, and Elisa Port, MD, discuss what every woman should know about skin and breast cancer.

4.89M Reach

GEN - Genetic Engineering and Biotechnology News - September 17, 2026

High-Grade Glioma Biology Varies by Age and Sex, Revealing Potential Treatment Targets

Pei Wang, PhD, and Nicole Tignor, PhD, discuss their research identifying candidate treatment targets and potential prognostic markers for high-grade glioma, an aggressive brain cancer, in children, adolescents, and young adults.

No reach data

Medical Xpress - September 17, 2026

A new AI-powered test offers more accurate prediction of breast cancer recurrence risk

Joseph Sparano, MD, discusses his research demonstrating that an AI model offers more accurate predictions of recurrence risk in patients with early-stage breast cancer than the widely used 21-gene Recurrence Score.

1.89M Reach

SciTechDaily - September 23, 2026

Just 5% of Pancreatic Cancer Cells Can Shield an Entire Tumor From Immune Attack

Brian Brown, PhD, and Chiara Falcomatà, PhD, a postdoctoral fellow at the Icahn School of Medicine at Mount Sinai, discuss their research, which found that small populations of pancreatic cancer cells can create localized immune-protective niches that shield tumors from immune attack, potentially opening new avenues for making immunotherapy more effective against one of the deadliest forms of cancer.

1.73M Reach

Drug Discovery News - September 25, 2026

High-grade gliomas show distinct biology across age and sex

Pei Wang, PhD, and Nicole Tignor, PhD, discuss their research identifying candidate treatment targets and potential prognostic markers for high-grade glioma, an aggressive brain cancer, in children, adolescents, and young adults.

No reach data

The ASCO Post - September 24, 2026

New AI Model Outperforms Oncotype DX for Predicting Recurrence Risk in Breast Cancer

Joseph Sparano, MD, discusses his research demonstrating that an AI model offers more accurate predictions of recurrence risk in patients with early-stage breast cancer than the widely used 21-gene Recurrence Score.

62.5k Reach